Claims for Patent: 9,029,146

Summary for Patent: 9,029,146

Title:	Mesenchymal stem cell conditioned medium
Abstract:	We disclose a method of preparing a conditioned cell culture medium, the method comprising the steps of: (a) culturing a mesenchymal stem cell (MSC), a descendent thereof or a cell line derived therefrom in a cell culture medium; and (b) optionally isolating the cell culture medium; in which the mesenchymal stem cell (MSC) is obtained by propagating a cell obtained by dispersing a embryonic stem (ES) cell colony, or a descendent thereof, in the absence of co-culture in a serum free medium comprising FGF2.
Inventor(s):	Lim; Sai Kiang (Singapore, SG), Lye; Elias (Singapore, SG)
Assignee:	Agency for Science, Technology and Research (Singapore, SG)
Application Number:	12/377,398
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,029,146
Patent Claims:	1. A method of preparing a conditioned cell culture medium, the method comprising the steps of: (a) dispersing a colony of embryonic stem (ES) cells in the absence of collagenase; (b) culturing the dispersed cells of step (a) in the absence of co-culture, in a serum free medium comprising fibroblast growth factor 2 (FGF2), wherein the resulting adherent cells comprise mesenchymal stem cells (MSCs); (c) and isolating conditioned cell culture medium from the culture of step (b). 2. The method of claim 1, in which the embryonic stem cell colony is a human embryonic stem cell colony (hESC) or an embryoid body. 3. The method of claim 1, in which the serum free medium further comprises one or both of: (i) platelet-derived growth factor AB (PDGF AB), and (ii) epidermal growth factor (EGF). 4. A method of treating a disease, the method comprising administering conditioned medium from a human MSC culture to an individual suffering from such disease, thereby treating the disease, wherein the human MSC culture is derived from cultured embryonic stem cell, wherein the conditioned medium is obtained by: (a) dispersing a colony of embryonic stem (ES) cells in the absence of collagenase; (b) culturing the dispersed cells of step (a) in the absence of co-culture, in a serum free medium comprising fibroblast growth factor 2 (FGF2), wherein the resulting adherent cells comprise mesenchymal stem cells (MSCs); (c) and isolating conditioned cell culture medium from the culture of step (b). 5. The method of claim 4 wherein the conditioned medium is administered in a pharmaceutical composition comprising a pharmaceutically acceptable excipient, diluent or carrier. 6. The method of claim 4, in which the MSC cell culture comprises cells selected as CD105+CD24-. 7. The method of claim 4, in which the cultured embryonic stem cells comprise huES9 or H1 embryonic stem cells. 8. A method of treating an ischemic injury, the method comprising administering a composition comprising conditioned medium from a human MSC culture derived from cultured embryonic stem cells, thereby treating the ischemic injury, wherein the conditioned medium is prepared by a method comprising the steps of: (a) dispersing a colony of embryonic stem (ES) cells in the absence of collagenase; (b) culturing the dispersed cells of step (a) in the absence of co-culture, in a serum free medium comprising fibroblast growth factor 2 (FGF2), wherein the resulting adherent cells comprise mesenchymal stem cells (MSCs); (c) and isolating conditioned cell culture medium from the culture of step (b). 9. The method of claim 8 wherein the ischemic injury comprises myocardial infarction or ischemic reperfusion injury. 10. The method of claim 8 wherein the conditioned medium is administered in a pharmaceutical composition comprising a pharmaceutically acceptable excipient, diluent or carrier. 11. The method of claim 8, in which the MSC cell culture comprises cells selected as CD105+CD24-. 12. The method of claim 8, in which the cultured embryonic stem cells comprise huES9 or H1 embryonic stem cells. 13. A method of promoting wound healing, bone formation, bone graft or the engraftment of a bone marrow transplant, or treating a dermatologic disorder, asthma, orthopaedic disease or bone marrow disease, the method comprising administering a composition comprising conditioned medium from a human MSC culture derived from cultured embryonic stem cells, thereby treating the condition or disease, wherein the conditioned medium is prepared by a method comprising the steps of: (a) dispersing a colony of embryonic stem (ES) cells in the absence of collagenase; (b) culturing the dispersed cells of step (a) in the absence of co-culture, in a serum free medium comprising fibroblast growth factor 2 (FGF2), wherein the resulting adherent cells comprise mesenchymal stem cells (MSCs); (c) and isolating conditioned cell culture medium from the culture of step (b). 14. The method of claim 13 wherein the conditioned medium is administered in a pharmaceutical composition comprising a pharmaceutically acceptable excipient, diluent or carrier. 15. The method of claim 13, in which the MSC cell culture comprises cells selected as CD105+CD24-. 16. The method of claim 13, in which the cultured embryonic stem cells comprise huES9 or H1 embryonic stem cells.

Details for Patent 9,029,146

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965		2025-09-02